| Identification | Back Directory | [Name]
Butanamide, 4,4,4-trifluoro-N-[(1S)-1-methyl-2-oxo-2-[[(6S)-2,3,5,6-tetrahydro-9-methoxy-3,3-dimethyl-5-oxo-1H-pyrrolo[1,2-a][1]benzazepin-6-yl]amino]ethyl]- | [CAS]
2064292-78-8 | [Synonyms]
Butanamide, 4,4,4-trifluoro-N-[(1S)-1-methyl-2-oxo-2-[[(6S)-2,3,5,6-tetrahydro-9-methoxy-3,3-dimethyl-5-oxo-1H-pyrrolo[1,2-a][1]benzazepin-6-yl]amino]ethyl]- | [Molecular Formula]
C23H28F3N3O4 | [MOL File]
2064292-78-8.mol | [Molecular Weight]
467.48 |
| Hazard Information | Back Directory | [Uses]
LY3056480 is a gamma-secretase inhibitor (GSI) that inhibits Notch signaling. LY3056480 improves mild to moderate sensorineural hearing loss and is safe and tolerable. Intratympanic administration of LY3056480 induces hair cell regeneration and partial hearing recovery in mammals[1]. | [References]
[1] Schilder AGM, et al. A phase I/IIa safety and efficacy trial of intratympanic gamma-secretase inhibitor as a regenerative drug treatment for sensorineural hearing loss. Nat Commun. 2024 Mar 1;15(1):1896. DOI:10.1038/s41467-024-45784-0 |
|
|